[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.129.96. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 161
Citations 0
Comment & Response
March 2016

Inaccurate Reporting of Insulin Reimbursement—Reply

Author Affiliations
  • 1The Program On Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
JAMA Intern Med. 2016;176(3):408-409. doi:10.1001/jamainternmed.2015.8101

In Reply As the authors of the 2 letters point out, it was not possible for us to fully characterize net insulin costs to Medicaid programs because of the secrecy of data on the total amounts of manufacturer rebates to Medicaid or average manufacturer prices (AMP), which are protected as companies’ trade secrets by confidentiality agreements and federal statutes. Because of the importance of these measures, the Department of Justice recently initiated an inquiry into how Lilly’s service agreements with wholesalers affects the calculation and reporting of AMP as part of the Medicaid drug rebate program.1

First Page Preview View Large
First page PDF preview
First page PDF preview
×